A welcome side effect: Novartis anti-inflammatory may cut risk of lung cancer, study finds
A Novartis anti-inflammatory drug sharply reduced lung cancer rates in a global study that also found it cut cardiovascular risk for heart attack survivors.
It was big news earlier this summer when a groundbreaking study of 10,000 patients found that an anti-inflammatory drug significantly reduced the risk of cardiovascular complications in heart attack survivors. Now, the researchers have found that the drug had a surprising (and welcome) side effect: It also sharply cut the rates of lung cancer.
Lead investigator Dr. Paul Ridker of Brigham and Women’s Hospital showed that the biologic drug canakinumab from Novartis () — which has thus far only
